Introduction
Fanconi anemia (FA) is an autosomal recessive disorder characterized by congenital malformations, progressive marrow failure and a predisposition to acute myelogenous leukemia and solid tumors. For the bone marrow failure, it has been universally accepted and proven that allogeneic stem cell transplantation (SCT) is curative;
1-5 the presence of myelodysplasia or a clonal abnormality, however, seems to be a poor prognostic factor for the FA patients in general 6, 7 and is, therefore, likely to adversely affect the outcome of SCT although there is paucity of data in this regard. [8] [9] [10] Here we offer an update of our experience at King Faisal Specialist Hospital and Research Center (KFSHRC) in 11 patients with FA who presented with myelodysplasia and/ or clonal abnormalities including one who presented with frank acute myeloid leukemia (AML); five of these patients have been reported earlier. All the patients underwent allogeneic SCT using a uniform radiation-containing conditioning regimen.
Patients and methods
This study is a retrospective analysis of data collected on patients treated at KFSHRC; the study was approved by the Research Advisory Council (RAC) at KFSHRC.
Patients
From January 2001, through May 2007, 50 patients with various degrees of bone marrow failure due to FA were referred to the section of pediatric SCT at KFSHRC for allogeneic SCT. Upon referral, all the patients had chromosomal breakage studies with mitomycin-C and/or Diepoxybutane (DEB) to confirm the diagnosis of FA anemia; the median time from the diagnosis of FA till SCT was 6.4 months (range, 1-124 months), some patients were followed for long periods of time before SCT because the families elected to postpone it. Prior to SCT, all the patients underwent morphologic and cytogenetic examination of their bone marrow and of the 50 patients referred during this period, 11 patients showed evidence of myelodysplasia, leukemia and/or clonal abnormality and are the subject of this report. There were 7 females and 4 males, the median age at the time of SCT was 10.8 years (range, 6.2-15 years); the patients had diverse cytogenetic abnormalities: 4 had deletion of 5q, 1 had deletion of 1q, 1 had deletion of 22q, 2 had monosomy 7, 1 had chromosome 20 abnormalities and 2 had no clonal abnormality despite the evident myelodysplasia morphologically (Table 1) .
Conditioning regimen
All the patients were conditioned with cyclophosphamide (CY) i.v. at 5 mg/kg on days À5, À4, À3 and À2 in addition to equine ATG at a dose of 40 mg/kg i.v. given on days À5, À4, À3 and À2; total-body irradiation (TBI) at 450 cGy was given on day À1. Mesna was administered to all the patients during the conditioning regimen to prevent hemorrhagic cystitis. The patients who developed allergic reactions to the equine product received rabbit ATG at 13 mg/kg on the same days.
Donors
Ten patients received transplants from matched related donors (9 from fully matched siblings and 1 from a oneantigen-mismatched sibling); all related donors had documented negative chromosomal breakage studies. Harvested marrows were not manipulated and the median CD34-positive cell count per kg of the recipient body weight was 4 Â 10 6 /kg (range, 2.7-10 Â 10 6 /kg). One patient received a one-antigen-mismatched unrelated cord blood unit.
The graft versus host disease prophylaxis
The graft versus host disease prophylaxis was with cyclosporine at the standard doses plus equine ATG at 20 mg/kg i.v. on days þ 2, þ 4, þ 6, þ 8, þ 10 and þ 12; cyclosporine was tapered and discontinued by 6 months after SCT unless patient had GVHD. The patients who developed allergic reactions to the equine product received rabbit ATG at 7 mg/kg on the same days. The recipient of the unrelated cord blood unit received in addition methylprednisolone 1 mg/kg i.v. from days þ 5 till þ 20 and tapered over 2 weeks. The addition of ATG to the GVHD prophylaxis regimen has been practiced previously in FA patients by us and by others because FA patients are considered at a higher risk for GVHD development. 1, 3, 4, 8, 11 Supportive care All the patients were treated in HEPA-filtered rooms and were isolated until engraftment; the engraftment was defined as an absolute neutrophil count of 500 Â 10 6 /l for 3 consecutive days. All the patients received intravenous immunoglobulins every 2 weeks at a dose of 500 mg/kg from day À4 until day þ 90, as well as, acyclovir 45 mg/kg/ day from day À3 to day þ 28. The patients also received Fluconazole therapy from day 0 until engraftment. No prophylactic ganciclovir was given, and CMV was monitored by weekly antigenemia tests. All blood products were leukocyte filtered and irradiated. Nine patients received GCSF.
Results

Engraftment
All the patients engrafted, the median time of engraftment was 16 days (range, 12-33 days). The median time for a self-sustained platelet count of 20 Â 10 9 /l was 27 days (range, 17-75 days). The engraftment was further confirmed by donor-recipient chimerism studies at least once during the first 3 months post-SCT, then at one year post-SCT. (Before February 2002, chimerism was documented using variable non-tandem repeats analysis for same sex transplants and using fluorescent in situ hybridization for opposite sex transplants; thereafter, it was documented using the short tandem repeats method). The test was done on peripheral blood (granulocytes and lymphocytes). All the patients demonstrated full (100%) donor chimerism.
In the beginning, the first 5 patients had post-SCT bone marrow studies (morphology and cytogenetic) at engraftment to ensure the disappearance of the abnormal pre-SCT findings; all 5 patients had normal marrows with disappearance of the abnormal clone if present before SCT; for the subsequent patients, however, we opted to rely on the chimerism studies to determine the success of the transplant.
Graft vs host disease Acute GVHD, grade 2 or higher, occurred in 2 patients (18.2%); 1 of them responded to steroid therapy and the other progressed to limited chronic GVHD but eventually went into remission. Chronic GVHD also occurred in another patient, and the patient responded well to the steroid therapy.
Regimen-related toxicities
The protocol was overall well tolerated, all patients developed mucositis requiring analgesia; no cases of venoocclusive disease of the liver or hemorrhagic cystitis were noted. Seven patients developed CMV infection based on positive CMV antigenemia test, all received pre-emptive ganciclovir therapy; 1 progressed to CMV pneumonitis. No secondary malignancies have been observed thus far.
Follow-up and causes of death Ten patients are alive, well and fully engrafted with a median follow-up of 46 months (range, 4.5-76 months). 
Discussion
Allogeneic SCT is curative for patients with FA and excellent disease free survival rates have been documented in several studies. [1] [2] [3] [4] [5] However, FA patients with myelodysplasia or clonal abnormality on presentation are a distinct group that requires more intensive conditioning prior to SCT as the presence of either may herald the development of AML and hence is a marker for an adverse outcome. 6, 7 This has been recognized even in the earlier publications addressing transplant in FA patients; in a cohort of 17 patients reported by Flowers et al. in 1992, 5 had evidence of leukemic transformation before SCT; 4 of them were conditioned with CY 120 mg/kg plus 12 GY fractionated TBI and 1 received busulfan 14 mg/kg and CY 100 mg/kg; 4 died of transplant-related mortality and 1 was reported alive with no evidence of disease, 8 years post-SCT. 12 When it later became clear that FA patients should receive lower doses of chemotherapy and radiation in order to avoid severe toxicity, 13,14 the accepted practice was still that those with evidence of myelodysplasia should be prepared for SCT more intensively; in the latest update of their experience, Socie´at al reported 5 patients with FA and myelodysplasia on presentation who were prepared with thoraco-abdominal irradiation plus CY 40 mg/kg instead of the 20 mg/kg routinely used for FA patients with no myelodysplasia; the authors reported an 8 year survival of 75%. 2 Increasing the dose of CY to 60 or 80 mg/kg has permitted the transplanters to eliminate radiation from the preparatory regimens for FA patients but attempts to apply the non-radiation regimens in patients with myelodysplasia or clonal abnormalities have not been successful; Zanis-Neto et al. 5 used only CY 60-80 mg/kg to condition their FA patients, but the 2 patients with cytogenetic abnormalities on presentation experienced delayed graft failure after the SCT with this regimen; 1 of them was salvaged with a second SCT.
Fludarabine, an excellent agent used lately with increased frequency in reduced intensity regimens, has also been explored in the conditioning of patients with FA. [15] [16] [17] [18] Tan et al. 17 recently reported their experience using fludarabine with cytoxan and ATG; of the 11 transplanted patients, 1 presented with myelodysplasia and cytogenetic abnormalities, patient relapsed almost 5 months after the transplant, and died from his disease about 48 months later despite a second SCT. Bitan et al.,
18 on the other hand, reported more encouraging results with the use of fludarabine plus cytoxan and/or busulfan in addition to ATG in the preparation, 1 of their patients had myelodysplasia and 2 had frank leukemia pre-SCT; 2 of the 3 patients engrafted, and 1 had graft rejection but was rescued with a second SCT using fludarabine, busulfan and alemtuzumab; all three were reported alive and disease-free at the time of report (Table 2) .
Even more uncertainties surround the management of patients presenting with frank AML since patients with AML generally have a much better prognosis if they were in remission before SCT and FA patients were usually believed to have low tolerance to induction chemotherapy, but Mehta et al. 19 have recently shown that FA patients can tolerate chemotherapy with clearance of disease; allogeneic Blasts in all 5 patients Present in 2 patients CY (40 mg/kg)/TAI (500 cGy) 8-year survival estimate 75% Zanis-Neto et al. 5 
2
No dysplastic features Present in both patients CY (60 mg/kg), no radiation Graft failure in both, one patient deceased, and one was salvaged with a 2nd SCT Philpott et al. SCT remains nevertheless the only decisive therapy for these patients. In our experience, the CY/TBI regimen has been associated with tolerable toxicity. Our long-term followup confirms the 4 patients previously reported with successful outcome 8 to remain alive and well. By using the same regimen, 6 additional patients have been successfully transplanted since; 1 of them from a partially matched unrelated cord blood unit. Consequently, out of 11 transplanted patients, we have now a total of 10 who are alive, well and free of disease with a median follow-up of almost 4 years. This is the largest series of such patients treated uniformly in a single institution (Table 3) .
We therefore conclude that SCT from matched related donors or partially matched unrelated cord using cytoxan and TBI for conditioning is curative for FA patients presenting with leukemia, myelodysplasia, and/or abnormal clone, it appears to be relatively well tolerated. Patients presenting with frank leukemia should probably be treated with chemotherapy to induce remission before SCT. 
